Mancini Anthony: insider trades.
Mancini Anthony reported 12 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($4.6M), across 1 company.
- Transactions
- 12
- Purchases (P)
- 0
- Sales (S)
- 10
- Companies
- 1
- Name as filed
- Mancini Anthony
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Revolution Medicines, Inc. (RVMD) | Officer · See Remarks | 12 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-25 | Revolution Medicines, Inc. | S | 3,121 | $200.54 | 39,765 | Form 4 |
| 2026-09-25 | Revolution Medicines, Inc. | M | 3,121 | $33.62 | 42,886 | Form 4 |
| 2026-09-24 | Revolution Medicines, Inc. | S | 587 | $200 | 39,765 | Form 4 |
| 2026-09-18 | Revolution Medicines, Inc. | S | 1,764 | $196.94 | 40,352 | Form 4 |
| 2026-09-16 | Revolution Medicines, Inc. | S | 1,747 | $199.3 | 42,116 | Form 4 |
| 2026-09-16 | Revolution Medicines, Inc. | S | 27 | $195.05 | 43,863 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | S | 2,420 | $205.05 | 45,369 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | S | 1,179 | $206.1 | 44,190 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | S | 300 | $207.17 | 43,890 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | S | 6,019 | $203.28 | 53,319 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | M | 9,363 | $33.62 | 59,338 | Form 4 |
| 2026-09-10 | Revolution Medicines, Inc. | S | 5,530 | $204.14 | 47,789 | Form 4 |
Questions
What stock did Mancini Anthony buy or sell?
Mancini Anthony reported 12 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($4.6M), across 1 company.
Is Mancini Anthony the same person as other filers with this name?
This page covers SEC CIK 2124509 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/mancini-anthony-2124509.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.